Related Experiment Video
Updated: May 10, 2025
08:24
Injections of Lipopolysaccharide into Mice to Mimic Entrance of Microbial-derived Products After Intestinal Barrier Breach
Published on: May 2, 2018
19.3K
LPS-Induced Liver Inflammation Is Inhibited by Psilocybin and Eugenol in Mice
Gregory Ian Robinson1, Marta Gerasymchuk1, Timur Zanikov1
1Department of Biological Sciences, University of Lethbridge, Lethbridge, AB T1K 3M4, Canada.
Pharmaceuticals (Basel, Switzerland)
|April 26, 2025
Summary
Psilocybin and eugenol show significant anti-inflammatory effects in a mouse model of liver inflammation. Post-treatment administration was more effective, with psilocybin alone demonstrating the strongest response against pro-inflammatory cytokines.
Area of Science:
- Pharmacology and Toxicology
- Immunology
- Hepatology
Background:
- Liver inflammatory diseases pose a significant global health challenge.
- Lipopolysaccharides (LPS) exacerbate liver inflammation via toll-like receptor 4 (TLR4) signaling.
Purpose of the Study:
- To evaluate the anti-inflammatory potential of psilocybin and eugenol.
- To investigate their effects in an LPS-induced liver inflammation model in mice.
Main Methods:
- C57BL/6J mice were administered psilocybin and/or eugenol before or after LPS injection.
- Key pro-inflammatory cytokine mRNA levels (IL-1β, IL-6, MCP-1, COX-2, TNF-α) were quantified.
- Histological analysis assessed liver tissue changes and inflammatory infiltration.
Main Results:
- Both psilocybin and eugenol, alone and combined, reduced LPS-induced pro-inflammatory cytokine mRNA.
- Post-treatment administration showed greater efficacy than pre-treatment.
- Psilocybin demonstrated the most potent anti-inflammatory effects, particularly on IL-1β, IL-6, and MCP-1. Combination with eugenol reduced COX-2 and TNF-α. Histology showed improved liver tissue and reduced inflammation. Eugenol's potential adverse effects were mitigated by psilocybin co-administration.
Conclusions:
- Psilocybin and its combination with eugenol are promising therapeutic agents for hepatic inflammation.
- These compounds may be beneficial in treating acute and chronic liver diseases.
- Further research is warranted to explore long-term effects, mechanisms, and human therapeutic efficacy.
